Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: Possible involvement of PPAR-γ agonistic property

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 2, 2013, Pages 124-136

  Singh, Birdavinder ^a   Sharma, Bhupesh ^a   Jaggi, Amteshwar S ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

acetylcholinesterase activity; Alzheimer's disease; inflammation; Morris water maze; oxidative stress; PPAR

Indexed keywords

2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; ACETYLCHOLINESTERASE; DONEPEZIL; GLUTATHIONE; LISINOPRIL; MYELOPEROXIDASE; NITRATE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOL DERIVATIVE; STREPTOZOCIN; TELMISARTAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BEHAVIOR; BLOOD CHEMISTRY; BRAIN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMENTIA; DRUG EFFICACY; ENZYME ACTIVITY; LEARNING; MAZE TEST; MEMORY; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL;

ACETYLCHOLINESTERASE ACTIVITY; ALZHEIMER'S DISEASE; INFLAMMATION; MORRIS WATER MAZE; OXIDATIVE STRESS; PPAR-Γ;

ALZHEIMER DISEASE; ANIMALS; BENZIMIDAZOLES; BENZOATES; CONGO RED; DEMENTIA; INJECTIONS, INTRAVENTRICULAR; LISINOPRIL; MAZE LEARNING; MICE; PPAR GAMMA; REACTION TIME; STAINING AND LABELING; STREPTOZOCIN;

EID: 84878068664     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312459977     Document Type: Article

References (91)

1. Stephan BC, Wells JC, Brayne C, et al. Increased fructose intake as a risk factor for dementia. J Gerontol A Biol Sci Med Sci. 2010 ; 65: 809-814
2. Kamat SM, Kamat AS, Grossberg GT. Dementia risk prediction: are we there yet?. Clin Geriatr Med. 2010 ; 26: 113-123
3. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 2010 ; 90: 465-494
4. Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2010 ; 4: 51-63
5. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010 ; 9: 387-398
6. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010 ; 9: 560-574
7. Cagnoni F, Njwe CA, Zaninelli A, et al. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag. 2010 ; 6: 549-559
8. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 2007 ; 6: 373-378 (Pubitemid 46389616)
9. Ciobica A, Bild W, Hritcu L, et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009 ; 109: 171-180
10. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010 ; 340: b5465
11. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res. 2010 ; 1352: 176-186
12. Hajjar IM, Keown M, Lewis P, et al. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen. 2008 ; 23: 77-83
13. Horiuchi M, Mogi M. Roles of activation of angiotensin II receptor subtypes in ischemic brain damage and cognitive function. Br J Pharmacol. 2011 ; 163: 1122-1130
14. Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci. 2007 ; 27: 8628-8635 (Pubitemid 47254272)
15. Sharma B, Singh N, Singh M. Modulation of celecoxib and streptozotocin-induced experimental dementia of Alzheimer's disease type by pitavastatin and donepezil. J Psychopharmacol. 2008 ; 22: 162-171 (Pubitemid 351322854)
16. Sharma B, Singh N, Jaggi AS. Exploration of HIV protease inhibitor indinavir as a memory restorative agent in experimental induced dementia. Pharmacol Biochem Behav. 2008 ; 89: 535-545
17. Blanco A, Alvarez S, Fresno M, et al. Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner. J Alzheimers Dis. 2010 ; 22: 493-505
18. Kaur B, Singh N, Jaggi AS. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol. 2009 ; 23: 557-566
19. Escribano L, Simón AM, Gimeno E, et al. Telmisartan rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010 ; 35: 1593-1604
20. Landreth G, Jiang Q, Mandrekar S, et al. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008 ; 5: 481-489 (Pubitemid 351952487)
21. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 2010 ; 23: 241-256
22. Napolitano M, Costa L, Palermo R, et al. Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res Bull. 2011 ; 85: 231-237
23. Fouad AA, Al-Sultan AI, Yacoubi MT, et al. Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration. Eur J Pharmacol. 2010 ; 637: 162-170
24. Jermendy G. Is type-2 diabetes mellitus preventable?. Orv Hetil. 2003 ; 144: 1909-1917
25. Hamed AA, Malek HA. Effect of telmisartan in experimentally induced diabetetes mellitus in rats. Int J Health Sci (Qassim). 2007 ; 1: 249-256
26. Matsumura T, Kinoshita H, Ishii N, et al. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-{gamma} in macrophages. Arterioscler Thromb Vasc Biol. 2011 ; 31: 1268-1275
27. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res. 2011 ; 45: 575-584
28. Morris RGM. Development of a water maze producer for studying spatial learning in the rats. J Neurosci Meth. 1984 ; 11: 47-60
29. Sharma B, Singh N. Pitavastatin and 4′-hydroxy-3′- methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr Neurovasc Res. 2010 ; 7: 180-191
30. Ellman GL, Courtney DK, Andres V, et al. A new and rapid colorimeteric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 ; 7: 88-95
31. Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylcholine/DTNB procedure. Toxicol Appl Pharmacol. 1970 ; 16: 764-772
32. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982 ; 126: 131-138 (Pubitemid 13203451)
33. Grisham MB, Benoit JN, Granger DN. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol. 1990 ; 186: 729-742 (Pubitemid 20280020)
34. Ohokawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 ; 95: 351-358 (Pubitemid 9194347)
35. Beutler E, Duron O, Kelly B. Improved method for the determination of blood glutathione. J Lab Clinical Med. 1963 ; 61: 882-888
36. Lowry OH, Rosebrough NJ, Far AL, et al. Protein measurement with folin-phenol reagent. J Biol Chem. 1951 ; 193: 265-275
37. Hou D, Wang Y, Zhou L, et al. Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease. Chin Med J. 2008 ; 121: 2320-2323
38. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension. 2009 ; 54: 782-787
39. Mogi M, Li JM, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008 ; 375: 446-449
40. Zhang SL, Yang XJ, Liu TF, et al. Effect and mechanism of jiannao yizhi decoction on learning and memory in rats with similar Alzheimer's disease. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 ; 28: 529-531
41. Rinwa P, Kaur B, Jaggi AS, et al. Involvement of PPAR-gamma in curcumin-mediated beneficial effects in experimental dementia. Naunyn Schmiedebergs Arch Pharmacol. 2010 ; 381: 529-539
42. Parle M, Singh N. Reversal of memory deficits by atorvastatin and simvastatin in rats. Yakugaku Zasshi. 2007 ; 127: 1125-1137 (Pubitemid 47035644)
43. Packard MG, Teather LA, Bazan NG. Effect of intra-striated injectins of platelet-activating factor and PAF antagonist BN 52021 on memory. Neurobiol Learn Mem. 1996 ; 66: 176-182 (Pubitemid 26423877)
44. Camarasa J, Rodrigo T, Pubill D, et al. Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res. 2010 ; 62: 450-456
45. Tota S, Awasthi H, Kamat PK, et al. Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res. 2010 ; 209: 73-79
46. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci. 1998 ; 112: 1199-1208 (Pubitemid 28519002)
47. Mayer G, Nitsch R, Hoyer S. Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. Brain Res. 1990 ; 532: 95-100 (Pubitemid 20384645)
48. Hoyer S, Muller D, Plaschke K. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm. 1994 ; 44: S259 - S268
49. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late onset sporadic Alzheimer's disease (SAD). A mini review. J Neural Transm. 2000 ; 109: 991-1002 (Pubitemid 34762337)
50. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer' s disease: an update. J Neural Transm. 2000 ; 109: S341 - S360
51. Agrawal R, Tyagi E, Shukla R, et al. A Study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology. 2009 ; 56: 779-787
52. Shoham S, Bejar C, Kovalev E, et al. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol. 2003 ; 184: 1043-1052 (Pubitemid 38182835)
53. Grünblatt E, Koutsilieri E, Hoyer S, et al. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis. 2006 ; 9: 261-271 (Pubitemid 44253344)
54. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002 ; 51: 1076-1082 (Pubitemid 34438352)
55. Spitaler MM, Graier WF. Vascular targets of redox signalling in diabetes mellitus. Diabetologia. 2002 ; 45: 476-494 (Pubitemid 34533826)
56. Kumaran D, Udayabanu M, Kumar M, et al. Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience. 2008 ; 155: 626-639
57. Savaskan E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res. 2005 ; 2: 29-35 (Pubitemid 41389257)
58. Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 2011 ; 342: 143-147
59. Kim JM, Uehara Y, Choi YJ, et al. Mechanism of attenuation of pro-inflammatory Ang II-induced NF-κB activation by genistein in the kidneys of male rats during aging. Biogerontology. 2011 ; 12: 537-550
60. Yasar S, Zhou J, Varadhan R, et al. The use of angiotensin-converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women. Clin Pharmacol Ther. 2008 ; 84: 119-126 (Pubitemid 351861493)
61. Barnes JM, Barnes NM, Costall B, et al. Angiotensin II inhibits the release of [3H] acetylcholine from rat entorhinal cortex in vitro. Brain Res. 1989 ; 491: 136-143 (Pubitemid 19159084)
62. Barnes JM, Barnes NM, Costall B, et al. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res. 1990 ; 507: 341-343 (Pubitemid 20054121)
63. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003 ; 61: 76-80 (Pubitemid 36818750)
64. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005 ; 37: 289-305 (Pubitemid 39330191)
65. Haraguchi T, Takasaki K, Naito T, et al. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Neurosci Lett. 2009 ; 464: 151-155
66. Ismail H, Mitchell R, McFarlane SI, et al. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep. 2010 ; 10: 32-36
67. Kasahara Y, Taguchi A, Uno H, et al. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res. 2010 ; 1340: 70-80
68. Hwang SJ, Kim JH, Shim JW, et al. Peroxisome proliferator-activated receptor-gamma expression in the lung tissue of obese rats. Yonsei Med J. 2011 ; 52: 495-501
69. Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004 ; 52: 649-650 (Pubitemid 38480653)
70. Tan J, Wang JM, Leenen FH. Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens. 2005 ; 18: 158-164 (Pubitemid 40332543)
71. Wyss JM, Kadish I, Van Groen T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens. 2003 ; 25: 455-474 (Pubitemid 37204430)
72. Haraguchi T, Iwasaki K, Takasaki K, et al. Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. Brain Res. 2010 ; 1353: 125-132
73. Kurihara T, Ozawa Y, Shinoda K, et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci. 2006 ; 47: 5545-5552 (Pubitemid 46723808)
74. Kobayashi T, Kawamata T, Shibata N, et al. Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A (2) level in experimental stroke. J Neurotrauma. 2009 ; 26: 2355-2364
75. Jung KH, Chu K, Lee ST, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther. 2007 ; 322: 1051-1058 (Pubitemid 47295814)
76. Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav. 2009 ; 91: 554-559
77. Hajjar I, Hart M, Milberg W, et al. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr. 2009 ; 9: 48
78. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 ; 10: 43-53
79. Fatehi-Hassanabad Z, Tasker RA. Peroxisome proliferator-activated receptors-gamma PPAR-gamma) activation confers functional neuroprotection in global ischemia. Neurotox Res. 2011 ; 19: 462-471
80. Glatz T, Stock I, Nguyen-Ngoc M, et al. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischemic brain. J Hypertens. 2010 ; 28: 1488-1497
81. Pereira MP, Hurtado O, Cárdenas A, et al. Telmisartan and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab. 2006 ; 26: 218-229 (Pubitemid 43151578)
82. Hyong A, Jadhav V, Lee S, et al. Telmisartan, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res. 2008 ; 1215: 218-224
83. Zhao X, Strong R, Zhang J, et al. Neuronal PPAR gamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009 ; 29: 6186-6195
84. Nicolakakis N, Aboulkassim T, Ongali B, et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci. 2008 ; 28: 9287-9296
85. Halvorsen B, Heggen E, Ueland T, et al. Treatment with the PPAR gamma agonist telmisartan downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol. 2010 ; 162: 267-273
86. Zhang Q, Hu W, Meng B, et al. PPARgamma agonist telmisartan is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res. 2010 ;:
87. Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res. 2007 ; 4: 159-164 (Pubitemid 46557505)
88. Sodhi RK, Singh N, Jaggi AS. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol. 2011 ; 384: 115-124
89. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and telmisartan reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry. 2010 ; 15: 272-285
90. Dong H, Yuede CM, Coughlan CA, et al. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res. 2009 ; 1303: 169-178
91. Maelicke A, Hoeffle-Maas A, Ludwig J, et al. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci. 2010 ; 40: 135-137